PARP1 and metabolic dysfunction-associated steatotic liver disease: Wenting et al. [6] observed that puerarin treatment reduced TNF-α expression by inhibiting the TLR4/MyD88/NF-κB pathway in adipose tissue, and Shuai et al. [33] reported that puerarin reduced hepatic fat accumulation by attenuating PARP-1 in NAFLD.